Abstract:OBJECTIVE:Lung cancer is one of the deadliest malignancies. The immune checkpoint-blockade (ICB) tumor therapy has led to striking improvement of long-term survival for some lung cancer patients. However, the response rate of immunotherapy is still low for lung cancer. Studying the tumor microenvironment (TME) should shed light on improvement of immunotherapy of lung cancer. Interleukin-33 (IL-33), an "alarmin" cytokine, has been implicated in tumor associated immune responses and inflammatory diseases of the lung. The role of IL-33 in lung cancer progression, however, remains elusive. This study is designed to characterize IL-33 expression in lung tumor tissues and establish the clinical significance of IL-33 in non-small cell lung cancer lung cancer (NSCLC).MATERIALS AND METHODS:Tumor tissue specimens from patients suffering from NSCLC were analyzed for expression of IL-33 protein by immunohistochemistry and expression of IL-33 and ST2 mRNA by RT-quantitative PCR (RT-QPCR). The expression data were analyzed for their association with clinical and pathological parameters of NSCLC. In addition, the association between expression levels of IL-33 mRNA and patient survival was determined using 5 independent expression profiling datasets of human lung cancer.RESULTS AND CONCLUSION:The expression levels of IL-33 and ST2 were significantly down-regulated in both adenocarcinoma and squamous cell carcinoma of the lung when compared to adjacent normal lung tissues. In addition, the level of IL-33 protein was inversely correlated with tumor grade and size. Moreover, analysis of TCGA and GEO lung cancer expression datasets revealed that higher expression levels of IL-33 mRNA were correlated with longer overall survival of patients suffering from adenocarcinoma of the lung. These data indicate that the expression levels of IL-33 are inversely associated with lung cancer progression, consistent with the hypothesis that IL-33 is involved in immune surveillance of NSCLC.

Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment

Interleukin-38 Promotes Skin Tumorigenesis in an IL-1Rrp2-dependent Manner.

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

IL-38 promotes the development of prostate cancer

Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling

The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression

Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy

Interleukin-38 promotes skin tumorigenesis via regulation of epidermal cell hyperplasia and pro-tumorigenic microenvironment in an IL-1Rrp2-dependent manner.

Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes

Lower Expression Level of IL-33 is Associated with Poor Prognosis of Pulmonary Adenocarcinoma.

Role of interleukin-8 in lung cancer

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

Interleukin-9 Promotes Tumorigenesis Through Augmenting Angiogenesis in Non-Small Cell Lung Cancer.

LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma

Interleukin -1β Promotes Lung Adenocarcinoma Growth and Invasion Through Promoting Glycolysis via p38 Pathway

Tumor-infiltrating CD45RO + memory cells correlate with favorable prognosis in patients with lung adenocarcinoma.

Interleukin-8 Modulates Growth And Invasiveness Of Estrogen Receptor-Negative Breast Cancer Cells

Aberrant Expression and Prognostic Potential of IL-37 in Human Lung Adenocarcinoma

IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.

Association between interleukin-36 and tumor progression in non-small cell lung cancer

IL-36β promotes anti-tumor effects in CD8+ T cells by downregulating micro-RNA let-7c-5p